Numico Research   Report issue

For profit Phase 2
Founded: Wageningen Netherlands (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2001
NCT00224432
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Alternative names

Numico Research Wageningen, the Netherlands

Active Ingredients

Drugs in Phase 2 Trials (1)

isomaltulose (1 trial)

Drugs in Other Trials (2)

bifidobacterium rhamnosus (1 trial)

lactobacillus rhamnosus (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3